|
|
 |
 |
| We need your donations to support our
seed money
grant program
for new research as well as our educational and support activities. |
|
 |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
 |
 |
 |
|
Noscapine Inhibits Human Prostate Cancer Progression and Metastases in the nude Mouse Model
The opium alkaloid noscapine as a low toxic tubulin stabiler was reported in previous studies that it inhibits the growth of several human and murine neoplasms including lymphoma , thymoma , melanoma and breast cancer with no significant toxic effects in tissues with active cell proliferation such as bone marrow , spleen and intestine. We reported that daily oral noscapine treatment (300 mg/Kg) administered to PC 3 human prostate cancer-bearing immunodeficient mice (n=10) revealed a significant reduction of tumor volume. Tumor inhibition rate of 60%. Total tumor weight was 0.42+/- 0.23 in noscapine treated group versus 0.97 +/- 0.31 in the vehicle treated group (P< 0.001)
This was achieved with no identifiable toxicity. Furthermore, noscapine treatment resulted in a slow incidence of metastasisi in the experimental animals compare with that of the vehicle treated animals. The metastsis rate was 30% in the noscapine treated group and 90% in the vehicle treated group, respectively (p<0.05). Our findings have shown that oral administration fo noscapine is effective agains the primary tumor growth and lymphatic metastasis on PC 3 human prostate cancer. These data warrant additional investigations of nontoxic therapeutic potential of noscapine for malignant disease, especially prostate cancer.
(Abstract from the 17th International Prostate Cancer Update Meeting. Vail, Colorado Feb 15, 2007)
Dr.
Israel "The Coach" Barken
|
|
|
|
|
|
